Related Experiment Videos
Quadruple therapy for ocular toxoplasmosis
1Department of Ophthalmology, University of Illinois Hospital Eye and Ear Infirmary, Chicago College of Medicine.
Summary
Quadruple therapy, including pyrimethamine and clindamycin, effectively treated ocular toxoplasmosis, improving vision in most patients. This treatment regimen demonstrated a favorable safety profile with minimal complications.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Parasitology
Background:
- Ocular toxoplasmosis is a significant cause of posterior uveitis.
- Effective treatment strategies are crucial for preserving vision in affected individuals.
Purpose of the Study:
- To evaluate the efficacy and safety of quadruple therapy for ocular toxoplasmosis.
- To assess treatment response rates and long-term outcomes.
Main Methods:
- Retrospective analysis of 36 patients (37 eyes) with ocular toxoplasmosis treated between 1973 and 1989.
- Quadruple therapy included pyrimethamine, trisulfapyrimidines, clindamycin, and prednisone.
- Treatment criteria included macular/optic disc involvement or visual acuity of 20/70 or worse.
Main Results:
- Vision improved in all but four cases.
- 54% of patients responded within 2 weeks, and 81% within 3 weeks.
- The primary complication was a skin rash in four patients; no severe adverse events were reported.
Conclusions:
- Quadruple therapy is an effective treatment for ocular toxoplasmosis.
- The regimen offers a favorable safety profile with rapid visual improvement.
- Recurrences were observed but responded to retreatment.